WEBINAR ON DEMAND
Duration: 1 hour

IsoPlexis’ groundbreaking intracellular signaling omics application allows users to uniquely analyze signaling cascades of many phosphoproteins directly from each single cell, across thousands of single cells in parallel. In this webinar event, learn why it’s a critical tool for the characterization of cancer cell resistance pathways and the development of durable targeted therapies to overcome resistance. Speakers will also discuss the solution’s impact on the fields of immune medicine and oncology, and highlight how it has been used in high-impact studies published in Cancer Cell, PNAS, and Nature Communications to predict and target therapeutic resistance in glioblastoma brain cancer and other metastatic cancers.

Reserve your spot to find out how you can accelerate your opportunities in the development of these sought-after, next generation targeted therapies.
 

SPEAKER

Sean Mackay
CEO & Co-Founder
IsoPlexis